Zanubrutinib - Generic Drug Details

What are the generic drug sources for zanubrutinib and what is the scope of freedom to operate?

Zanubrutinib is the generic ingredient in one branded drug marketed by Beone Medicines Usa and is included in two NDAs. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Zanubrutinib has one hundred and five patent family members in thirty-two countries.

One supplier is listed for this compound.

Summary for zanubrutinib

International Patents:	105
US Patents:	13
Tradenames:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	38
Clinical Trials:	174
What excipients (inactive ingredients) are in zanubrutinib?	zanubrutinib excipients list
DailyMed Link:	zanubrutinib at DailyMed

Recent Clinical Trials for zanubrutinib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Canadian Cancer Trials Group	PHASE2
BeOne Medicines	PHASE3
Alliance for Clinical Trials in Oncology	PHASE3

See all zanubrutinib clinical trials

Pharmacology for zanubrutinib

Drug Class	Kinase Inhibitor
Mechanism of Action	Bruton's Tyrosine Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for zanubrutinib

L01EL	Bruton's tyrosine kinase (BTK) inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for ZANUBRUTINIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BRUKINSA	Tablets	zanubrutinib	160 mg	218785	1	2025-11-13
BRUKINSA	Capsules	zanubrutinib	80 mg	213217	2	2023-11-14

US Patents and Regulatory Information for zanubrutinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Beone Medicines Usa	BRUKINSA	zanubrutinib	TABLET;ORAL	218785-001	Jun 10, 2025		RX	Yes	Yes
Beone Medicines Usa	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		DISCN	Yes	No
Beone Medicines Usa	BRUKINSA	zanubrutinib	TABLET;ORAL	218785-001	Jun 10, 2025		RX	Yes	Yes	11,591,340

EU/EMA Drug Approvals for zanubrutinib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
BeiGene Ireland Ltd	Brukinsa	zanubrutinib	EMEA/H/C/004978Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL).	Authorised	no	no	no	2021-11-22

International Patents for zanubrutinib

Country	Patent Number	Title	Estimated Expiration
Singapore	11201901141W	CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF
Eurasian Patent Organization	201990519
Israel	325562

Supplementary Protection Certificates for zanubrutinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2989106	LUC00250	Luxembourg		PRODUCT NAME: ZANUBRUTINIB OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/21/1576 20211123
2989106	PA2022504	Lithuania		PRODUCT NAME: ZANUBRUTINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ; REGISTRATION NO/DATE: EU/1/21/1576 20211121
2989106	CR 2022 00008	Denmark		PRODUCT NAME: ZANUBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1576 20211123

Last updated: February 13, 2026

What Is Zanubrutinib and How Does It Fit into the Market?

Zanubrutinib (brand name: Brukinsa) is a Bruton’s tyrosine kinase (BTK) inhibitor developed by BeiGene. It is approved for treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström’s macroglobulinemia (WM). Its mechanism involves blocking BTK, a key enzyme in B-cell receptor signaling, which promotes the proliferation of malignant B-cells.

Market-wise, zanubrutinib is positioned against competitors like ibrutinib (Imbruvica) from AbbVie and Johnson & Johnson, and acalabrutinib (Calquence) from AstraZeneca. Its focus on improved selectivity and reduced off-target effects aims to differentiate it.

How Has Zanubrutinib's Market Penetration Evolved?

Zanubrutinib launched in China in 2019 and gained regulatory approval in the United States in 2021. The drug has secured approvals in multiple territories, including China, the US, and the European Union, with broader approval under review or pending.

In China, BeiGene’s domestic market dominance offers rapid uptake. In the US, sales are emerging as clinical data supports efficacy and safety, especially for patients intolerant to ibrutinib. Sales figures are estimated as follows:

Year	Global Sales (USD million)	Notes
2021	Approx. 200	Initial launch, mostly in China
2022	Approx. 600	Entry into US and EU markets, expanding sales
2023	Estimated 1,200–1,500	Growth driven by expanded indications and markets

By 2023, analysts project zanubrutinib could surpass USD 1.5 billion globally, driven by further approvals and expanded indications, especially if additional Phase III studies confirm superiority over competitors or demonstrate impactful safety benefits.

What Are Key Market Opportunities and Challenges?

Opportunities:

• Expanding Indications: Beyond MCL, CLL, WM, preclinical trials explore use in other B-cell malignancies.
• Geographic Expansion: Focus on emerging markets with growing healthcare infrastructure.
• Partnerships and Licensing: BeiGene’s collaborations can accelerate global presence.

Challenges:

• Competitive Landscape: Ibrutinib and acalabrutinib dominate early, with established sales.
• Pricing and Reimbursement: As with all oncology drugs, reimbursement policies heavily influence sales.
• Safety Profile: Any safety concerns or adverse events could impact market acceptance.

What Are the Financial Trajectories and Investment Outlook?

BeiGene reported revenues of approximately USD 400 million in 2022, with zanubrutinib contributing a significant share. Profitability remains limited due to high R&D and marketing costs, but sales growth aligns with increased market penetration.

Potential revenue projections for 2025 suggest USD 2 billion globally, assuming continued approval and market expansion. Significant investment in clinical trials and regulatory filings could bolster long-term revenue, but commercialization risks remain.

Pricing strategies typically favor premium pricing based on clinical benefits. For example, in the US, zanubrutinib's annual price approximates USD 150,000, comparable to competitors.

How Do Regulatory Developments Influence Future Market Dynamics?

Regulatory agencies are critical to zanubrutinib’s trajectory. The US FDA approved it under a Priority Review, signaling its importance. Trials like the ASPEN study compare it directly to ibrutinib, aiming to establish superiority or non-inferiority.

Timely approvals in Europe and Canada depend on ongoing data submissions. Further approvals for additional indications could substantially increase market size.

What Strategic Moves Are Notable in the Competitive Arena?

BeiGene is focusing on demonstrating clinical advantages over existing BTK inhibitors. It has initiated trials in combination therapy, seeking to position zanubrutinib as part of multi-drug regimens. Patent protection for zanubrutinib extends into the late 2020s and early 2030s.

Licensing deals, including partnerships with global pharmaceutical firms, aim to expand manufacturing capacity and accelerate distribution.

Summary Tables and Data

Key Data Point	Details
Approved indications	MCL, CLL, WM
Peak sales forecast (2025)	USD 2 billion
Price per patient (US)	USD 150,000 per year
R&D expenditure (2022)	USD 200 million
Market share (estimated 2023)	15-20% of BTK inhibitor segment

Key Takeaways

• Zanubrutinib channels growth through expanded indications and geographic reach.
• Competition remains intense from established BTK inhibitors, but clinical advantages could shift market share.
• Regulatory and reimbursement landscapes are key success factors.
• Sales growth is projected through 2025, with potential for long-term dominance if clinical results support superior positioning.

FAQs

Q1: What differentiates zanubrutinib from other BTK inhibitors?
It shows higher selectivity for BTK, reducing off-target effects and potentially lowering side effects like atrial fibrillation seen with ibrutinib.

Q2: What are the main markets for zanubrutinib?
China, the US, and select EU countries hold the largest potential, with emerging markets expanding as approvals are secured.

Q3: When is zanubrutinib expected to reach peak sales?
Analysts estimate around 2025, with USD 2 billion in global revenue, contingent on approval of additional indications and continued clinical success.

Q4: What are the patent protections around zanubrutinib?
Patent rights extend into the early to mid-2030s, providing BeiGene with a period of market exclusivity.

Q5: How does pricing impact zanubrutinib’s market penetration?
Premium pricing based on clinical benefits limits access in some healthcare systems, but reimbursement strategies and value-based pricing are critical drivers of sales.

---

References

[1] Bloomberg Intelligence. "Zanubrutinib Market Analysis," 2023.
[2] BeiGene. "Brukinsa (Zanubrutinib) Prescribing Information," 2022.
[3] Evaluate Pharma. "Oncology Market Reports," 2023.
[4] U.S. Food and Drug Administration. "FDA Approvals Data," 2021, 2022.